1,024 material Form 8-K filings that 799 companies we cover made with the SEC in August 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
CAVA Group reported fiscal second-quarter 2025 results for the period ended July 13, 2025, with CAVA Revenue up 20.3% to $278.2 million on 16 net new restaurant openings and same restaurant sales growth of 2.1%. Net income fell to $18.4 million from $19.7 million a year earlier, while Adjusted EBITDA rose 22.6% to $42.1 million, and the company cut its full-year same restaurant sales growth outlook to 4.0% to 6.0% from 6.0% to 8.0%.
CAVA Revenue grew 20.3% to $278.2 million versus $231.4 million in the prior-year quarter; total revenue was $280.6 million.
Net income was $18.4 million, down from $19.7 million; diluted EPS was $0.16 versus $0.17 a year earlier.
Adjusted EBITDA rose to $42.1 million from $34.3 million; CAVA Restaurant-Level Profit Margin was 26.3% versus 26.5%.
Updated fiscal 2025 guidance: same restaurant sales growth cut to 4.0% to 6.0%; net new openings raised to 68 to 70; Adjusted EBITDA unchanged at $152.0 million to $159.0 million.
Everus Construction Group reported second quarter 2025 revenues of $921.5 million, up 31.0% from a year earlier, and net income of $52.8 million, or $1.03 per diluted share, up from 76 cents. The company raised its full-year 2025 revenue guidance to $3.3 billion to $3.4 billion and its EBITDA guidance to $240 million to $255 million, indicating management expects higher results for the year.
Net income rose 35.4% to $52.8 million; diluted EPS was $1.03 versus 76 cents in the second quarter of 2024.
EBITDA rose 35.6% to $84.2 million; backlog reached $3.0 billion as of June 30, 2025, up 23.9% from June 30, 2024.
2025 revenue guidance was raised from $3.0 billion to $3.1 billion to $3.3 billion to $3.4 billion; EBITDA guidance was raised from $210 million to $225 million to $240 million to $255 million.
Management will discuss the results on a webcast at 10:30 a.m. EDT on August 13, 2025.
Lumentum reported fiscal fourth-quarter 2025 net revenue of $480.7 million, up 55.9% from a year earlier and 13.1% from the prior quarter, with GAAP net income of $213.3 million, or $2.96 per diluted share, helped by a $224.7 million income tax benefit. The company expects first-quarter fiscal 2026 net revenue of $510 million to $540 million, which would be above the fourth-quarter level.
Q4 FY25 GAAP net income of $213.3 million ($2.96 per diluted share) compared with a GAAP net loss of $252.5 million in Q4 FY24; the quarter included a $224.7 million income tax benefit.
Q4 FY25 non-GAAP net income of $63.3 million, or $0.88 per diluted share, versus $40.9 million ($0.57) in Q3 FY25.
Fiscal 2025 net revenue of $1.65 billion, up 21.0% from $1.36 billion in fiscal 2024; GAAP net income of $25.9 million.
Q1 FY26 outlook: net revenue of $510 million to $540 million, non-GAAP operating margin of 16.0% to 17.5%, and non-GAAP diluted EPS of $0.95 to $1.10.
H&R Block reported fiscal 2025 results for the year ended June 30, 2025, with revenue up 4.2% to $3.8 billion and diluted EPS from continuing operations up 6.8% to $4.42. The Board also raised the quarterly dividend 12% to $0.42 per share and gave fiscal 2026 guidance with adjusted diluted EPS of $4.85 to $5.00. Shareholders also received $600 million through dividends and buybacks during the year, and a roughly $0.50 per-share tax benefit that management had expected in the fourth quarter was delayed beyond fiscal 2025.
Total revenue of $3.8 billion, up $150.6 million, or 4.2%, from the prior year
Diluted EPS from continuing operations of $4.42, up $0.28 or 6.8%; adjusted EPS of $4.66, up 5.7%
Quarterly dividend raised 12% to $0.42 per share, payable October 6, 2025 to holders of record as of September 4, 2025
Fiscal 2026 outlook: revenue of $3.875 billion to $3.895 billion and adjusted diluted EPS of $4.85 to $5.00
Madison Square Garden Sports Corp. (MSGS) reported fiscal 2025 revenues of $1.04 billion, up 1%, but operating income fell to $14.8 million and the company recorded a net loss of $22.4 million for the year. In the fourth quarter, revenue fell 10% to $204.0 million and the company posted an operating loss, mainly due to higher direct operating expenses, which matters to shareholders because profit fell sharply even as annual sales edged up.
Fiscal 2025 revenues were $1,039.2 million, up $12.1 million, or 1%, from the prior year
Fiscal 2025 operating income was $14.8 million, down $131.2 million; net loss was $22.4 million, or $0.93 per diluted share
Fourth-quarter revenues were $204.0 million, down $23.3 million, or 10%; operating loss was $22.6 million versus operating income of $52.3 million a year earlier
Fourth-quarter direct operating expenses rose $47.1 million, or 44%, including $42.8 million of higher net provisions for certain team personnel transactions
Cardinal Health reported fourth-quarter and fiscal 2025 results and raised its fiscal 2026 non-GAAP diluted EPS outlook to $9.30 to $9.50, a $0.20 increase from the preliminary range given at its June 2025 Investor Day. Fourth-quarter revenue was flat at $60.2 billion, while non-GAAP diluted EPS rose 13% to $2.08, and the company said results were helped by segment profit growth. The company also announced that its Specialty Alliance unit has agreed to acquire Solaris Health, a urology management services organization.
Q4 FY2025 revenue was $60.2 billion, flat year over year; non-GAAP diluted EPS rose 13% to $2.08
Fiscal 2025 GAAP diluted EPS was $6.45; non-GAAP diluted EPS rose 9% to $8.24
FY2026 non-GAAP EPS outlook raised to $9.30 to $9.50, from $9.10 to $9.30 previously
Definitive agreement to acquire Solaris Health, announced in a separate news release on August 12, 2025
Liquidia reported second quarter 2025 total revenue of $8.8 million, up from $3.7 million a year earlier, as YUTREPIA began commercial sales after FDA approval on May 23, 2025. The net loss widened to $41.6 million, or $0.49 per share, from $28.7 million, or $0.38 per share, as selling, general and administrative expenses rose to $38.8 million. Cash and cash equivalents were $173.4 million at June 30, 2025, and the filing includes no financial guidance.
Total revenue was $8.8 million versus $3.7 million a year earlier, including $6.5 million in YUTREPIA product sales.
Net loss was $41.6 million, or $0.49 per share, compared with $28.7 million, or $0.38 per share.
SG&A expenses were $38.8 million versus $19.9 million, including a $5.8 million rise in legal fees tied to YUTREPIA litigation.
As of August 8, specialty pharmacies reported more than 900 unique patient prescriptions and more than 550 patient starts.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.